Skye Bioscience, Inc. (NASDAQ:SKYE) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET
Company Participants
Bernie Hertel – Head of Investor Relations
Punit Dhillon – President and Chief Executive Officer
Kaitlyn Arsenault – Chief Financial Officer
Chris Twitty – Chief Scientific Officer
Tu Diep – Chief Operating Officer
Puneet Arora – Chief Medical Officer
Conference Call Participants
Kristen Kluska – Cantor Fitzgerald & Co.
Edward Tenthoff – Piper Sandler & Co.
Jay Olson – Oppenheimer & Co. Inc.
Andy Hsieh – William Blair & Company
George Farmer – Scotiabank
Jonathan Wolleben – Citizens JMP Securities
Albert Lowe – Craig-Hallum Capital Group
Operator
Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today. At this time, I would like to welcome everyone to the Skye Bioscience Year-End 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session.
I would now like to turn the conference over to Bernie Hertel, Head of Investor Relations. Please go ahead.
Bernie Hertel
Hello, and thank you all for participating in today’s call. Leading the discussion today are Punit Dhillon, Skye’s President and CEO; and Kaitlyn Arsenault, Skye’s CFO.
Before we begin, I’d like to caution that comments made during this conference call will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Skye’s expectations regarding its development activities, timelines and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today’s date and the Company undertakes no obligation to
Read the full article here